<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-207" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Coronary Arterial Pressure Evaluation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Devanabanda</surname>
            <given-names>Arvind Reddy</given-names>
          </name>
          <aff>Zucker School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Hemindermeet</given-names>
          </name>
          <aff>Ascension St John Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arvind Reddy Devanabanda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hemindermeet Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-207.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Coronary artery pressure measurement is fundamental in treating angiographically intermediate lesions. Inappropriate percutaneous coronary intervention (PCI) in non-flow limiting coronary stenosis can lead lead to complications of stent thrombosis and a potential increase in mortality. It is, thus, important to understand physiological interpretation to guide coronary revascularization. This activity reviews coronary arterial pressure measurement tools and highlights the role of the interventional cardiology team in improving the clinical outcomes of patients undergoing PCI.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications of physiological assessment using FFR and iFR.</p></list-item><list-item><p>Describe the technical aspects of performing a coronary pressure measurement with iFR.</p></list-item><list-item><p>Outline appropriate evaluation of the potential complications and clinical significance of coronary arterial pressure measurement.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to advance coronary artery pressure measurements and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=207&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=207">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-207.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The diagnosis of epicardial coronary artery disease (CAD) during left heart catheterization is made through the angiographic interpretation of percent narrowing of the arterial lumen. The severe stenotic lesions typically have an appearance of at least 70 percent diameter reduction. However, there is often inter-observer variability in the assessment of intermediate lesions (40% to 70% stenosis). These lesions may&#x000a0;have functional impairment of flow distally to&#x000a0;cause myocardial ischemia and eventually left ventricular contractile dysfunction. The physiologic assessment of such lesions is paramount in the cardiac catheterization lab.&#x000a0;</p>
      </sec>
      <sec id="article-207.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>
<bold>Coronary Anatomy&#x000a0;</bold>
</p>
        <p>The purpose of angiography is to visualize the coronary arteries, major branches, or anomalies. Angiography also studies plaque burden, calcification, thrombus, or aneurysms. The major epicardial coronary arteries are left anterior descending (LAD), left circumflex (LCx), and the right coronary artery (RCA). The LAD and LCx arise from the left main coronary artery (LM). The LM and RCA typically originate&#x000a0;from the left and right aortic sinus of Valsalva, respectively.&#x000a0;The branches of LAD&#x000a0;are called&#x000a0;diagonals and septals. The branches of the LCx are called obtuse marginals. The RCA usually bifurcates&#x000a0;into the right posterior descending artery (RPDA) and right posterolateral artery (RPL). RCA also gives acute marginal branches. These are visualized during an angiogram, and pressure measurement can be performed in these. The cardiac microvasculature is not discreetly visualized during cardiac catheterization.&#x000a0;</p>
        <p>
<bold>Physiology</bold>
</p>
        <p>The coronary arteries fill during diastole as the vigorous contraction of the heart during systole allows for little driving pressure. Using the principle of Ohm&#x02019;s law,&#x000a0;<italic toggle="yes">V = IR</italic>&#x000a0;(<italic toggle="yes">V</italic> is voltage difference<italic toggle="yes">, I</italic> is current, <italic toggle="yes">R </italic>is resistance), the coronary pressure and flow are directly related, assuming minimal resistance. The pressure gradient in the coronaries is the difference between a distal coronary bed and aortic root pressure. The pressure gradient could be derived by&#x000a0;measuring trans-stenotic gradient at rest or hyperemia, a direct coronary flow reserve (CFR) measurement, or the slope of the relationship between mean gradient and coronary flow. The two most&#x000a0;commonly used physiological tools&#x000a0;are fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR).&#x000a0;</p>
      </sec>
      <sec id="article-207.s4" sec-type="Indications">
        <title>Indications</title>
        <p>Functional&#x000a0;assessment of a lesion with fractional flow reserve&#x000a0;(FFR) or instantaneous wave-free ratio (iFR) is appropriate in case&#x000a0;of intermediate stenosis&#x000a0;(40% to 70% diameter reduction angiographically), multivessel disease, serial coronary stenoses, nonculprit lesion in acute coronary syndrome, saphenous vein graft disease severity and post-intervention assessment. The various recommendations by major society guidelines are as below:&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>The 2014 European Society of Cardiology guidelines recommend the use of FFR to detect a hemodynamically relevant coronary lesion in stable patients when other evidence of ischemia is not available (Class I, Level of Evidence A).<xref ref-type="bibr" rid="article-207.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>The 2012 American College of Cardiology/American Heart Association guidelines recommends revascularization of coronary stenoses with FFR &#x02264; 0.8.<xref ref-type="bibr" rid="article-207.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>The 2017 Society of Cardiovascular Angiography and Interventions guidelines recommend that if no stress test is available or if the stress results are indeterminate, the FFR &#x02264; 0.8 can be used to guide revascularization.<xref ref-type="bibr" rid="article-207.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-207.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no specific contraindications to the measurement of IFR/FFR. Adenosine infusion to measure FFR should be avoided in patients with active bronchial asthma.</p>
      </sec>
      <sec id="article-207.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>The miniaturized pressure sensor, which is embedded into a&#x000a0;coronary wire is able to carry out pressure measurements with high fidelity. The pressure sensor contains piezo-electric sensors and is made by St. Jude and Philip Volcano. The sensor is typically located at the proximal end of the radiopaque wire tip. The disadvantage of these wires is the potential for signal interference at connecting points. These wires typically have a signal drift of &#x0003c; 7 mmHg/hr. FFR is a ratio of pressure distal to stenosis (Pd) relative to proximal pressure (Pa) during maximal hyperemia or vasodilation [4]. On the other hand,&#x000a0;iFR equipment relies on the cardiac mechanics of wave generation. A wave-free period (WFP) exists in diastole, and during this period, the intracoronary pressure and flow decrease in a linear fashion, and the microvascular resistance are minimal. Therefore iFR relies on this WFP to derive&#x000a0;coronary pressure assessment without inducing hyperemia.<xref ref-type="bibr" rid="article-207.r4">[4]</xref></p>
      </sec>
      <sec id="article-207.s7" sec-type="Personnel">
        <title>Personnel</title>
        <p>The personnel performing coronary arterial pressure measurements are interventional cardiologists with the assistance of a cardiology fellow or a technician and a&#x000a0;nurse.</p>
      </sec>
      <sec id="article-207.s8" sec-type="Preparation">
        <title>Preparation</title>
        <p>The preparation involves the availability of the&#x000a0;equipment&#x000a0;and installed software.</p>
      </sec>
      <sec id="article-207.s9" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>After obtaining arterial access via the radial or common femoral artery, the index vessel is engaged with a guiding catheter.&#x000a0;The pressure wire product packaging is opened under sterile conditions, flushed with saline, and then zeroed. The wire tip is typically shaped per standard practice based on angulation and tortuosity of the vessel. The wire is then advanced through an introducer and&#x000a0;guiding catheter into the coronary artery. Normalization of the waveform is obtained, at the tip of the guide catheter. Pressure wire is then parked, just distal to the stenosis. An iFR measurement is recorded. An iFR &#x02264; 0.89 may prompt the interventionalist to perform revascularization.</p>
        <p>Similarly, during FFR measurement, the pressure wire is placed distal to the stenosis, and a hyperemic agent such as adenosine is administered (15 to 30 mcg bolus in RCA and 20-40 &#x000b5;g bolus in the LM or 140 mcg/kg/min for 3 min via IV infusion). FFR calculation is then obtained. FFR values of less than 0.80 indicate significant stenosis.</p>
      </sec>
      <sec id="article-207.s10" sec-type="Complications">
        <title>Complications</title>
        <p>The complications are similar to any PCI and include vessel dissection, perforation, embolism, and coronary spasm. Other complications of a diagnostic catheterization include vascular complications, contrast induced nephropathy, stroke, myocardial infarction, arrhythmias and death.</p>
      </sec>
      <sec id="article-207.s11" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Large randomized controlled trials are now available, which has studied the primary endpoint of all-cause mortality, myocardial infarction (MI), or revascularization in 12 to 24 months in patients treated with iFR/FFR guided PCI. The DEFER trial enrolled 325 patients and showed that patients with FFR values greater than 0.75 did not benefit from percutaneous coronary intervention (PCI); however,&#x000a0;patients with FFR less than 0.75 had symptomatic improvement.<xref ref-type="bibr" rid="article-207.r5">[5]</xref>&#x000a0;The FAME trial randomized&#x000a0;1005 patients to either FFR guided PCI or PCI by angiography alone. The primary endpoint of&#x000a0;death, MI, or repeat revascularization at 12 months was lower in the FFR guided group and was sustained at 24 months.<xref ref-type="bibr" rid="article-207.r6">[6]</xref> Similarly, the FAME-2 trial enrolled 1220 patients with a FFR value of &#x02264;0.80 who were randomized to either PCI and optimal medical therapy (OMT) versus OMT alone. The trial was prematurely terminated&#x000a0;due to an increased incidence of urgent revascularization in the OMT only group.<xref ref-type="bibr" rid="article-207.r7">[7]</xref></p>
        <p>The DEFINE-FLAIR and IFR SWEDEHEART trials showed the noninferiority of iFR compared to FFR with the primary outcome of major adverse cardiovascular events at 1 year.<xref ref-type="bibr" rid="article-207.r8">[8]</xref>&#x000a0;A pooled patient-level meta-analysis of these 2 trials revealed&#x000a0;that iFR based deferral of revascularization was greater than FFR&#x000a0;with similar outcomes&#x000a0;in both groups.<xref ref-type="bibr" rid="article-207.r9">[9]</xref></p>
      </sec>
      <sec id="article-207.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>After identification of an intermediate severity lesion during angiography, coronary artery pressure measurement with FFR or iFR should be done&#x000a0;to determine&#x000a0;the use of further intervention, which has shown to improve clinical outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-207.s13" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Coronary artery pressure measurement is an invasive procedure performed&#x000a0;in the cath lab with an interprofessional team approach. While an intervnetional cardiologist perform the procedure with a tech or fellow, the nursing staff assists with continuous monitoring of patients clinical status, delivering medications and handing all equipment.&#x000a0;</p>
      </sec>
      <sec id="article-207.s14" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>The interprofessional team&#x000a0;of nurses, radiation technologists, fellow, and the interventional cardiologist closely monitors vital signs, technical aspects, sterility of the procedure along with the safety of the staff and patient from&#x000a0;radiation exposure.&#x000a0;</p>
      </sec>
      <sec id="article-207.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=207&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=207">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/207/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=207">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-207.s16">
        <fig id="article-207.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Schematic showing the origination of the coronary arteries. Contributed from Users: Dr Michael Veltman Heart-Scan.org michael.veltman and adaption and further labeling: Mikael H&#x000e4;ggstr&#x000f6;m (CC BY-SA 3.0 https://creativecommons.org/licenses/by-sa/3.0/)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Coronary__Artery__digram" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-207.s17">
        <title>References</title>
        <ref id="article-207.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kolh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alfonso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Collet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cremer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Head</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>J&#x000fc;ni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kappetein</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Kastrati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Knuuti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Landmesser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Laufer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Schauerte</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sousa Uva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stefanini</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Taggart</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Torracca</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Valgimigli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wijns</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Witkowski</surname>
                <given-names>A</given-names>
              </name>
              <collab>European Society of Cardiology Committee for Practice Guidelines</collab>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Achenbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baumgartner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bax</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Deaton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>&#x000c7;</given-names>
              </name>
              <name>
                <surname>Fagard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hasdai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoes</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Knuuti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kolh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Linhart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nihoyannopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Piepoli</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sirnes</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Tamargo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Tendera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wijns</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <collab>EACTS Clinical Guidelines Committee</collab>
              <name>
                <surname>Sousa Uva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Achenbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pepper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anyanwu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Badimon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baumbach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beygui</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bonaros</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>De Carlo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Deaton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dobrev</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dunning</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eeckhout</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gielen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hasdai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Luckraz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mahrholdt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paparella</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rastan</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sanmartin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sergeant</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Silber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamargo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>ten Berg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van Geuns</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>Wassmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wendler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <collab>Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery</collab>
              <collab>European Association of Percutaneous Cardiovascular Interventions</collab>
            </person-group>
            <article-title>2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).</article-title>
            <source>Eur J Cardiothorac Surg</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>517</fpage>
            <page-range>517-92</page-range>
            <pub-id pub-id-type="pmid">25173601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-207.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fihn</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Gardin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blankenship</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Dallas</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Foody</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Hinderliter</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kligfield</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Munger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Prager</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Sabik</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Sikkema</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spertus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SV</given-names>
              </name>
              <collab>American College of Cardiology Foundation</collab>
              <collab>American Heart Association Task Force on Practice Guidelines</collab>
              <collab>American College of Physicians</collab>
              <collab>American Association for Thoracic Surgery</collab>
              <collab>Preventive Cardiovascular Nurses Association</collab>
              <collab>Society for Cardiovascular Angiography and Interventions</collab>
              <collab>Society of Thoracic Surgeons</collab>
            </person-group>
            <article-title>2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2012</year>
            <month>Dec</month>
            <day>18</day>
            <volume>60</volume>
            <issue>24</issue>
            <fpage>e44</fpage>
            <page-range>e44-e164</page-range>
            <pub-id pub-id-type="pmid">23182125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-207.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Calhoon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Dehmer</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Grantham</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Maddox</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons.</article-title>
            <source>J Nucl Cardiol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>1759</fpage>
            <page-range>1759-1792</page-range>
            <pub-id pub-id-type="pmid">28608183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-207.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f6;tberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nijjer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Escaned</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>The Evolving Future of Instantaneous&#x000a0;Wave-Free Ratio and Fractional Flow&#x000a0;Reserve.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Sep</month>
            <day>12</day>
            <volume>70</volume>
            <issue>11</issue>
            <fpage>1379</fpage>
            <page-range>1379-1402</page-range>
            <pub-id pub-id-type="pmid">28882237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-207.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bech</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>De Bruyne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pijls</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>de Muinck</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Hoorntje</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Escaned</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stella</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Boersma</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bartunek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koolen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Wijns</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial.</article-title>
            <source>Circulation</source>
            <year>2001</year>
            <month>Jun</month>
            <day>19</day>
            <volume>103</volume>
            <issue>24</issue>
            <fpage>2928</fpage>
            <page-range>2928-34</page-range>
            <pub-id pub-id-type="pmid">11413082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-207.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tonino</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>De Bruyne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pijls</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ikeno</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van' t Veer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klauss</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Manoharan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Engstr&#x000f8;m</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oldroyd</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Ver Lee</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>MacCarthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Fearon</surname>
                <given-names>WF</given-names>
              </name>
              <collab>FAME Study Investigators</collab>
            </person-group>
            <article-title>Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>Jan</month>
            <day>15</day>
            <volume>360</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-24</page-range>
            <pub-id pub-id-type="pmid">19144937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-207.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Bruyne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pijls</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Kalesan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Barbato</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tonino</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Piroth</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jagic</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>M&#x000f6;bius-Winkler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rioufol</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>MacCarthy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Engstr&#x000f6;m</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oldroyd</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Mavromatis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Manoharan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Verlee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frobert</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Curzen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>J&#x000fc;ni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fearon</surname>
                <given-names>WF</given-names>
              </name>
              <collab>FAME 2 Trial Investigators</collab>
            </person-group>
            <article-title>Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Sep</month>
            <day>13</day>
            <volume>367</volume>
            <issue>11</issue>
            <fpage>991</fpage>
            <page-range>991-1001</page-range>
            <pub-id pub-id-type="pmid">22924638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-207.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dehbi</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Al-Lamee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Petraco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nijjer</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bhindi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lehman</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sapontis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vrints</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Khashaba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Belle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Krackhardt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bojara</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Going</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>H&#x000e4;rle</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Indolfi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Niccoli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ribichini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yokoi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takashima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kikuta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Erglis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vinhas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Canas Silva</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baptista</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Alghamdi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hellig</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Doh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Brugaletta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alegria-Barrero</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meuwissen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piek</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>van Royen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sezer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Mario</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Sharp</surname>
                <given-names>ASP</given-names>
              </name>
              <name>
                <surname>Talwar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Samady</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seto</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jeremias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kharbanda</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Serruys</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Escaned</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>May</month>
            <day>11</day>
            <volume>376</volume>
            <issue>19</issue>
            <fpage>1824</fpage>
            <page-range>1824-1834</page-range>
            <pub-id pub-id-type="pmid">28317458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-207.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f6;tberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Gudmundsdottir</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Sandhall</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Danielewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jakobsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>&#x000d6;hagen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Omerovic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calais</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lindroos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maeng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>T&#x000f6;dt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Venetsanos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>K&#x000e5;regren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hauer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Panayi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erlinge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fr&#x000f6;bert</surname>
                <given-names>O</given-names>
              </name>
              <collab>iFR-SWEDEHEART Investigators</collab>
            </person-group>
            <article-title>Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>May</month>
            <day>11</day>
            <volume>376</volume>
            <issue>19</issue>
            <fpage>1813</fpage>
            <page-range>1813-1823</page-range>
            <pub-id pub-id-type="pmid">28317438</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
